Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones Laotian Times Source: Author: | Date: 2025-09-02 12:00:00 Source: Author: | Date: 2025-09-02 12:00:00
Are prostaglandins really the most effective glaucoma therapy? Eyes On Eyecare Source: Author: | Date: 2025-09-01 18:54:00 Source: Author: | Date: 2025-09-01 18:54:00
Sharp Weight Loss from Childhood to Adulthood May Raise Glaucoma Risk: Study Shows Medical Dialogues Source: Author: | Date: 2025-09-01 15:15:00 Source: Author: | Date: 2025-09-01 15:15:00

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; and John Hovanesian, MD, FACS; discuss the importance of comprehensive…
Glaucoma techniques advance with innovative viscoelastic delivery Ophthalmology Times Source: Author: | Date: 2025-08-28 17:26:00 Source: Author: | Date: 2025-08-28 17:26:00
Another Win for GLP-1 Agonists? A Possible Reduced Risk of Uveitis MedPage Today Source: Author: | Date: 2025-08-28 15:24:00 Source: Author: | Date: 2025-08-28 15:24:00

(Image Credit: AdobeStock/rohane) “Modern devices for delivering viscoelastics during viscocanaloplasty have changed greatly over the past few years, resulting in better outcomes with improved ergonomics and user-friendliness for the surgeons who are performing the procedures,” said Edward Yung, MD, of…

The CCOI Myopia Workshop in Paris on September 8, 2025, will bring together global experts to address the rising epidemic of myopia. (Image credit: AdobeStock/racesy) As myopia rates continue to climb globally—emerging as a major concern not only in Asia…
Molecules found in eye fluid offer new hope for glaucoma detection The Brighter Side of News Source: Author: | Date: 2025-08-27 14:07:00 Source: Author: | Date: 2025-08-27 14:07:00

(Image Credit: AdobeStock) The first patient has been dosed in Qlaris Bio’s Phase II Nightingale clinical trial for QLS-111 in patients with normal tension glaucoma (NTG).1 The study, which is Qlaris Bio’s third phase 2 clinical trial of the company’s…